Key Takeaways:
Optimi Health Corp. closed its previously announced US$15 million underwritten public offering on May 21, securing funds to expand its psychedelic drug manufacturing and distribution into the United States market following its uplisting to the Nasdaq.
"Our proprietary AI technology investment platform can guide and identify investment themes,” said Michael Young, a board member of SRx Health Solutions, which recently invested in Optimi. “This gives us a unique opportunity to invest in companies with positive macro and industry trends."
The offering sold 2,400,000 common shares at a price of US$6.25 per share, with Joseph Gunnar & Co. acting as the sole book-running manager. The move to the Nasdaq Capital Market, under the ticker OPTH, became effective May 20. The company also recently completed a 1-for-30 share consolidation.
The capital injection and Nasdaq listing provide Optimi with increased visibility and funding to capitalize on a favorable regulatory environment, following a recent executive order aimed at accelerating psychedelic drug development. The funds are earmarked for scaling production, expanding into the U.S., and supporting sales growth for its GMP-grade psilocybin and MDMA products, although management retains broad discretion over the specific allocation.
The successful offering and uplisting come as the psychedelics industry gains momentum, partly driven by regulatory tailwinds. An executive order signed in April 2026 aims to accelerate the development of psychedelic drugs and improve coordination between the FDA and DEA.
This environment attracted investors like SRx Health Solutions and EMJ Crypto Technologies, which used a proprietary AI platform to identify Optimi as an investment. The platform highlighted Optimi's high insider ownership of approximately 30% and its strong corporate governance as key strengths.
This article is for informational purposes only and does not constitute investment advice.
